Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
XSpray Pharma AB
XSPRAYXspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company's product candidates include Dasynoc, a trailblazer, under approval phase for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib, under pivotal studies for the treatment of chronic myeloid leukemia; XS008, based on axitinib, under development for treatment of kidney cancer; and XS00Y under development phase. It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa for commercial production of Dasynoc. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden. Address: Scheeles vAeg 2, Solna, Sweden, 171 65
Analytics
Preço Alvo de Wall Street
967.3 SEKRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave XSPRAY
Análise de Dividendos XSPRAY
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos XSPRAY
Avaliação de ações XSPRAY
Relatório XSPRAY
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |